A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) (TALLY)

Conditions

Mental Health & Behavioral Research

Phase II

Volunteers
Health Professionals

What is the purpose of this trial?

The primary objective of the study is to evaluate the efficacy of BIIB104 in participants with CIAS, using the Working Memory Domain of the MATRICS Consensus Cognitive Battery (MCCB).

The secondary objectives of this study are to evaluate the safety and tolerability of BIIB104 in participants with CIAS, and to evaluate the efficacy of BIIB104 in participants with CIAS on measures of cognition, functioning, and psychiatric symptomology.

Ages
18 years - 50 years
Gender
Both

Find out more about who can participate in this trial

Trial with
Biogen MA, Inc.
Start Date
03/20/2020
End Date
04/06/2020

For more information about this study, contact:

Melanie Gonzales

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Deepak Cyril Dsouza, MBBS, MD
Professor of Psychiatry; Director Schizophrenia Neuropharmacology Research Group at Yale (SNRGY); Director, Neurobiological Studies Unit, VACHS; Director, VA-CMHC Schizophrenia Research Clinic

Sub-Investigators

Last Updated
11/17/2021
Study HIC
#2000026887

A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) (TALLY)

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Sub-Investigators

Contact Information